Clinical trials: sponsored by Institut Paoli-Calmettes
Cancer Of Pancreas
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor.
- Trial name
- GemSign-01 (NCT06046794)
- Testing
- Analyze of GemCore status
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for patients with acute myeloid leukemia (AML).
- Trial name
- ELIT-AML01 (NCT03597321)
- Testing
- prophylactic donor lymphocyte infusion (DLI)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Cancer
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
The goal of this observational study is to develop and validate a preoperative immunological signature for predicting postoperative pancreatic fistula (POPF) in adult patients undergoing pancreatic surgery for pancreatic cancer.
- Trial name
- NCT07827911
- Testing
- blood sampling
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Adenocarcinoma Metastatic
Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating…
- Trial name
- NCT07664891
- Testing
- Biopsy collection, Blood collection
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Institut Paoli-Calmettes
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia
FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) predominantly affect older adults, and their incidence continues to rise with advanced age.
- Trial name
- FT-RIC-HAPLO (NCT07598110)
- Testing
- fludarabine and treosulfan
- Volunteers
- 77 people
- Sponsor
- Institut Paoli-Calmettes
Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable
A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
Pancreatic cancer exhibits significant heterogeneity, which poses a major challenge in selecting the best treatment for patients from the very beginning of care.
- Trial name
- PRODIGE 104 B (NCT07592819)
- Testing
- mFOLFIRINOX (modified FOLFIRINOX)
- Volunteers
- 367 people
- Sponsor
- Institut Paoli-Calmettes
Acute Leukemia, Myelodysplastic Syndromes
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using…
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- HEMATO-BIO (NCT02320656)
- Testing
- Blood sampling, Bone marrow aspirate, Skin biopsy
- Where
- France
- Volunteers
- 650 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
The acute pain care, in particular after breast cancer surgery must be early and quickly effective, because a severe postoperative pain increases the risk of chronic pain and exposes to a risk of important embarrassment for the…
- Trial name
- NCT02525211
- Testing
- Ropivacaine, physiological saline
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Institut Paoli-Calmettes
Lung Cancer Metastatic, Locally Advanced Malignant Neoplasm
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types.
- Conditions
- Lung Cancer Metastatic, Locally Advanced Malignant Neoplasm, Non Hodgkin Lymphoma, Urologic Neoplasms
- Trial name
- IMMUNO-SUP (NCT03595813)
- Testing
- Blood sample collection, Biopsy collection
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Institut Paoli-Calmettes
Hematological Malignancy
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF)…
- Trial name
- DLI-NK (NCT01853358)
- Testing
- NK Cell infusion
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Institut Paoli-Calmettes
Rectal Cancer
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Standard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity.
- Trial name
- ETAP (NCT02584985)
- Testing
- ETAP, Standard Transabdominal Laparoscopic Proctectomy
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Tumor
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
- Trial name
- PACAomics (NCT01692873)
- Testing
- suspected pancreatic tumor
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Predictive Clinical and Biological Parameters in Breast Cancer
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
- Trial name
- BC-BIO (NCT01521676)
- Testing
- molecular alteration
- Where
- 2 sites in France
- Volunteers
- 749 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
This study is based upon the following points: 1. Resistance to trastuzumab, either primary or secondary, is a clinically relevant issue. 2.
- Trial name
- PIKHER2 (NCT01589861)
- Testing
- BKM120 + lapatinib
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Paoli-Calmettes
Neoplasm Metastasis
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors
PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery…
- Trial name
- PERMED01 (NCT02342158)
- Testing
- biopsy or surgical sampling, blood sampling
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
The overall rationale of this study evaluating tolerance and efficacy of LY2780301 in combination with paclitaxel in HER2-negative, inoperable locally advanced or metastatic breast cancer (MBC) is based on : the medical need in…
- Trial name
- TAKTIC (NCT01980277)
- Testing
- LY2780301 + paclitaxel
- Where
- 2 sites in France
- Volunteers
- 68 people
- Sponsor
- Institut Paoli-Calmettes
Ovarian Cancer, Endometrium Cancer
Predictive Clinical and Biological Parameters in Gynecological Cancer
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
- Conditions
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- Trial name
- GC-BIO (NCT01977274)
- Testing
- gynecological cancer
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Institut Paoli-Calmettes
Bladder Cancer
Evaluation of VISIOCYT Bladder Cytology in Real Life
The study will be offered to all consecutive patients undergoing scheduled cystoscopy at the Hospitalisation De Jour (HDJ) Chirurgicale, either as part of a diagnostic approach in the event of suspected bladder tumor (exploration…
- Trial name
- VISIOCYT2 (NCT06072027)
- Where
- France
- Volunteers
- 701 people
- Sponsor
- Institut Paoli-Calmettes